Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome

Int J Mol Sci. 2020 Dec 1;21(23):9172. doi: 10.3390/ijms21239172.

Abstract

Sjögren's syndrome (SS) is a systemic autoimmune disorder affecting approximately 3% of the population in the United States. This disease has a female predilection and affects exocrine glands, including lacrimal and salivary glands. Dry eyes and dry mouths are the most common symptoms due to the loss of salivary and lacrimal gland function. Symptoms become more severe in secondary SS, where SS is present along with other autoimmune diseases like systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. It is known that aberrant activation of immune cells plays an important role in disease progression, however, the mechanism for these pathological changes in the immune system remains largely unknown. This review highlights the role of different immune cells in disease development, therapeutic treatments, and future strategies that are available to target various immune cells to cure the disease.

Keywords: B cell; Sjögren’s syndrome; T cell; autoimmune disease; cytokines; dry eye; dry mouth; immune cells; immunotherapy; inflammation; lacrimal gland; macrophages; salivary glands.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmunity
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • Biological Therapy* / methods
  • Combined Modality Therapy
  • Cytokines / metabolism
  • Disease Management
  • Disease Susceptibility* / immunology
  • Humans
  • Immunity, Innate*
  • Macrophages / immunology
  • Macrophages / metabolism
  • Salivary Glands / immunology
  • Salivary Glands / metabolism
  • Sjogren's Syndrome / immunology*
  • Sjogren's Syndrome / therapy*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Treatment Outcome

Substances

  • Cytokines